These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 6090050)

  • 21. Pharmacokinetics of ceftriaxone in humans.
    Patel IH; Chen S; Parsonnet M; Hackman MR; Brooks MA; Konikoff J; Kaplan SA
    Antimicrob Agents Chemother; 1981 Nov; 20(5):634-41. PubMed ID: 6275779
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-dose pharmacokinetics of ceftriaxone in infants and young children.
    Schaad UB; Stoeckel K
    Antimicrob Agents Chemother; 1982 Feb; 21(2):248-53. PubMed ID: 6280597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biliary excretion of amoxycillin and ceftriaxone after intravenous administration in man.
    Maudgal DP; Maxwell JD; Lees LJ; Wild RN
    Br J Clin Pharmacol; 1982 Aug; 14(2):213-7. PubMed ID: 6285946
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Elimination kinetics of cefotaxime and desacetyl cefotaxime in patients with renal insufficiency and during hemodialysis.
    Ohkawa M; Okasho A; Motoi I; Tokunaga S; Shoda R; Kawaguchi S; Sawaki M; Shimamura M; Hirano S; Kuroda K; Awazu S
    Chemotherapy; 1983; 29(1):4-12. PubMed ID: 6299656
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of cefaronide, ceftriaxone and cefoperazone in sheep.
    Guerrini VH; Filippich LJ; Cao GR; English PB; Bourne DW
    J Vet Pharmacol Ther; 1985 Jun; 8(2):120-7. PubMed ID: 4020943
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics of ceftriaxone in liver-transplant recipients.
    Toth A; Abdallah HY; Venkataramanan R; Teperman L; Halsf G; Rabinovitch M; Burckart GJ; Starzl TE
    J Clin Pharmacol; 1991 Aug; 31(8):722-8. PubMed ID: 1880231
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Human pharmacology of ceftriaxone (author's transl)].
    Le Van Thoi J; Koumare B; Lhoste F; Soussy CJ; Duval J
    Pathol Biol (Paris); 1982 Jun; 30(6):345-7. PubMed ID: 6287386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mezlocillin kinetics in hepatic insufficiency.
    Bunke CM; Aronoff GR; Brier ME; Sloan RS; Luft FC
    Clin Pharmacol Ther; 1983 Jan; 33(1):73-6. PubMed ID: 6217018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition of ceftriaxone in rat: application of a pharmacokinetic-protein binding model and comparison with cefotaxime.
    Hakim L; Bourne DW; Triggs EJ
    Xenobiotica; 1989 Aug; 19(8):815-22. PubMed ID: 2815824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of ceftriaxone after intravenous infusion and intramuscular injection.
    Scully BE; Fu KP; Neu HC
    Am J Med; 1984 Oct; 77(4C):112-6. PubMed ID: 6093511
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites.
    Hary L; Andrejak M; Leleu S; Orfila J; Capron JP
    Eur J Clin Pharmacol; 1989; 36(6):613-6. PubMed ID: 2776819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Absolute bioavailability of ceftriaxone after intramuscular administration to healthy volunteers.
    Delsignore R; Baroni CM; Crotti G; Mineo F; Butturini U; Ascalone V; Cisternino M
    Chemotherapy; 1983; 29(3):157-62. PubMed ID: 6307601
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. I. Theoretical considerations.
    McNamara PJ; Gibaldi M; Stoeckel K
    Eur J Clin Pharmacol; 1983; 25(3):399-405. PubMed ID: 6313379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of protein binding on cefmenoxime steady-state kinetics in critical patients.
    Reitberg DP; Cumbo TJ; Smith IL; Schentag JJ
    Clin Pharmacol Ther; 1984 Jan; 35(1):64-73. PubMed ID: 6317272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concentrations of ceftriaxone in serum and lung tissue.
    Just HM; Frank U; Simon A; Kaiser D; Daschner FD
    Chemotherapy; 1984; 30(2):81-3. PubMed ID: 6321115
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Single-dose pharmacokinetics of ceftriaxone in healthy Chinese adults.
    Zhou HH; Chan YP; Arnold K; Sun M
    Antimicrob Agents Chemother; 1985 Feb; 27(2):192-6. PubMed ID: 3985603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Volume of distribution terms for a drug (ceftriaxone) exhibiting concentration-dependent protein binding. II. Physiological significance.
    McNamara PJ; Gibaldi M; Stoeckel K
    Eur J Clin Pharmacol; 1983; 25(3):407-12. PubMed ID: 6313380
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Kinetic interactions between azlocillin, cefotaxime, and cefotaxime metabolites in normal and impaired renal function.
    Kampf D; Borner K; Möller M; Kessel M
    Clin Pharmacol Ther; 1984 Feb; 35(2):214-20. PubMed ID: 6319069
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A study of the relationship between dose and pharmacokinetics of ceftriaxone.
    Findlay CD; Brown RM; Allcock JE; Lowe PA; Wise R
    J Antimicrob Chemother; 1982 Jan; 9(1):57-62. PubMed ID: 6277840
    [No Abstract]   [Full Text] [Related]  

  • 40. [Ceftriaxone, a long-acting cephalosporin. Microbiological, kinetic and clinical study].
    Soranzo ML; Capra E; Angela GC; Eandi M; Salassa B; Lollini P; Musso E; Pizzo L; Spezia C; Di Nola F
    Minerva Med; 1983 Sep; 74(36):2093-102. PubMed ID: 6312379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.